FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
05/30/2022
Back to search
Official data from USPTO
CELLPROTHERA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
33
Latest update
05/30/2022
Trademark type
Combined
Nice classes
5, 10, 42, 44
Filing date
04/01/2020
Registration date
11/23/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
11/23/2021
Last transaction
11/23/2021
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
99
Owner location
FR
Examiner
BELL, MARLENE D
Law office
M90
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the stylized wording "CELLPROTHERA" and the letter "O" is completely shaded.
Holders and representatives
Holders
CELLPROTHERA
Representatives
Janet G Ricciuti JANET GILBERT RICCIUTI
Technical classification
Nice Classes
Class 5Class 10Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Biological preparations for cell culturescell culture mediaculture media for cell growth for medical biotechnologybiological reagents for molecular biologychemical reagents for medical use for biological processescarriers of culture media for medical usecellular function activating agentsserumsantibodiesall these products being for medical use
Class 10
Medical apparatus and instrumentsmedical devices in the nature of human and animal cellstem cells and cell-derived products and instruments for injection of cellstem cells and cell-derived productschambers for culturecentrifugation and isolation of cellstem cell and cell-derived for cell-based diagnosis and treatment; apparatus for cell culturenamely medical devices for human and animal cell culture diagnosis and treatment; medical instruments for cell culturenamely instruments for cell culture media and for potency testing of human and animal cell and cell-derived products for cell based treatment and diagnostic; medical apparatus and devices for cell separation techniquesmedical device and apparatus for human and animal cell selectionfor human cell immune and for cell dimension selection for the cell-based diagnosis and treatment
Class 42
Research and development services of new products in the field of biotechnologyscientific analysis services in the field of medical research laboratory services for medical purposes and for development of new products for medical research for third parties
Class 44
Services for medical care and treatmentnamely therapeutic treatments in the field of cell therapy and regenerative medicine; medical services for cell growthsampling and isolation for the production of cell and cell-derived human and animal cell productscell and stem cell graft injection therapy allowing for the regeneration of damaged tissues following age-related diseases or traumas for medical treatment services; services for medical analysis relating to treating individualsbehavioral analysis for medical purposestherapeutic treatmentnamely cell therapy for regenerative medicine
Publications
History of USPTO decisions and trademark events.
33 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
05/10/2022
FIMP
FINAL DISPOSITION PROCESSED
05/10/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
02/23/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
11/23/2021
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
10/29/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
10/06/2021
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
10/06/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/07/2021
PUBO
PUBLISHED FOR OPPOSITION
09/07/2021
GPNX
NOTIFICATION PROCESSED BY IB
09/04/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
08/18/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
08/18/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/18/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/30/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/21/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/21/2021
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
07/21/2021
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
03/08/2021
GNFR
FINAL REFUSAL E-MAILED
03/08/2021
CNFR
FINAL REFUSAL WRITTEN
03/08/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/27/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/27/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/27/2021
RFNT
REFUSAL PROCESSED BY IB
08/29/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
08/04/2020
RFRR
REFUSAL PROCESSED BY MPU
08/04/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
06/29/2020
CNRT
NON-FINAL ACTION WRITTEN
06/28/2020
DOCK
ASSIGNED TO EXAMINER
06/21/2020
MAFR
APPLICATION FILING RECEIPT MAILED
05/07/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/03/2020
SDRC
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
04/30/2020
Continuous trademark protection
Get notified about every new filing that threatens CELLPROTHERA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.